Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537658 | 1.00 | MEN1 (0.35) | MEN1NPC1ALPLALPIALPG | |
| SCHEMBL537707 | 0.78 | ALDH1A1 (0.36) | MEN1NPC1RAB9AKMT2AKDM1A | |
| SCHEMBL537708 | 0.78 | ALDH1A1 (0.36) | MEN1NPC1RAB9AKMT2AKDM1A | |
| SCHEMBL537626 | 0.71 | RAB9A (0.39) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL537625 | 0.71 | RAB9A (0.39) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL612814 | 0.66 | CYP1B1 (0.51) | MEN1NPC1RAB9AKMT2ANOS3 | |
| SCHEMBL612813 | 0.66 | CYP1B1 (0.51) | MEN1NPC1RAB9AKMT2ANOS3 | |
| SCHEMBL6824427 | 0.64 | MEN1 (0.57) | MEN1NPC1ALPLALPIALPG | |
| SCHEMBL11692993 | 0.64 | MEN1 (0.57) | MEN1NPC1ALPLALPIALPG | |
| SCHEMBL12589187 | 0.62 | ALDH1A1 (0.37) | MEN1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102365263-B | Polymerizable composition | BASF SE | 2015-04-01 | — | — | CN | disclosed |
| US-8940806-B2 | Polymerizable compositions | BASF SE (DE) | 2015-01-27 | — | — | US | disclosed |
| US-20120041093-A1 | POLYMERIZABLE COMPOSITIONS | BASF SE (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-2414324-A1 | POLYMERIZABLE COMPOSITIONS | BASF SE (DE) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112410-A1 | POLYMERIZABLE COMPOSITIONS | BASF SE (DE) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041093-A1 | POLYMERIZABLE COMPOSITIONS | H1-10, CBR1, NR1H2 | MEN1 2343/4885NPC1 2325/4885ALPL 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.